pioglitazone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
peroxisome proliferator activating receptor-gamma (PPAR-gamma) agonists, thiazolidinedione derivatives	2179	111025-46-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: pioglitazone glustin sepioglin pioglitazone hydrochloride pioglitazone HCl	Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPAR-gamma). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism. Molecular weight: 356.44 Formula: C19H20N2O3S CLOGP: 3.53 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 68.29 ALOGS: -4.91 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

pioglitazone
glustin
sepioglin
pioglitazone hydrochloride
pioglitazone HCl

Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPAR-gamma). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism.

Molecular weight: 356.44
Formula: C19H20N2O3S
CLOGP: 3.53
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 68.29
ALOGS: -4.91
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.80 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	83 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma)	0.01 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company	Orphan
July 15, 1999	FDA	TAKEDA PHARMS USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bladder cancer	538.02	11.95	159	22839	5407	63460617
Hypoglycaemia	448.33	11.95	276	22722	59789	63406235
Blood glucose increased	401.01	11.95	292	22706	83464	63382560
Cardiac failure congestive	187.97	11.95	198	22800	92235	63373789
Diabetes mellitus inadequate control	145.48	11.95	82	22916	15044	63450980
Glycosylated haemoglobin increased	140.76	11.95	75	22923	12323	63453701
Blood glucose decreased	128.07	11.95	85	22913	20867	63445157
Diabetic ketoacidosis	124.88	11.95	83	22915	20422	63445602
Oedema peripheral	113.68	11.95	227	22771	189284	63276740
Cardiac failure	84.96	11.95	131	22867	89011	63377013
Diabetic metabolic decompensation	79.35	11.95	28	22970	1682	63464342
Lactic acidosis	72.41	11.95	79	22919	38208	63427816
Pancreatitis	67.48	11.95	86	22912	48969	63417055
Systemic lupus erythematosus	63.11	11.95	3	22995	208915	63257109
Drug intolerance	62.98	11.95	17	22981	308644	63157380
Drug ineffective	61.87	11.95	185	22813	1044580	62421444
Myocardial infarction	61.41	11.95	121	22877	99772	63366252
Hyperglycaemia	58.53	11.95	74	22924	41793	63424231
Oedema	58.50	11.95	117	22881	97505	63368519
Bladder neoplasm	56.89	11.95	17	22981	599	63465425
Weight increased	54.14	11.95	212	22786	260580	63205444
Infusion related reaction	53.03	11.95	12	22986	245509	63220515
Glossodynia	52.66	11.95	3	22995	178873	63287151
Off label use	51.92	11.95	104	22894	674358	62791666
Bladder transitional cell carcinoma	51.34	11.95	16	22982	651	63465373
Macular oedema	51.30	11.95	26	22972	3851	63462173
Contraindicated product administered	48.30	11.95	10	22988	217638	63248386
Maternal exposure during pregnancy	47.03	11.95	11	22987	220051	63245973
Acute kidney injury	46.69	11.95	204	22794	263211	63202813
Pancreatitis acute	46.12	11.95	53	22945	27113	63438911
Coronary artery disease	43.32	11.95	56	22942	32321	63433703
Arthropathy	40.78	11.95	17	22981	234775	63231249
Diabetes mellitus	39.73	11.95	72	22926	55738	63410286
Pancreatic carcinoma	39.62	11.95	28	22970	7600	63458424
Wound	39.47	11.95	6	22992	163257	63302767
Weight decreased	39.28	11.95	201	22797	276597	63189427
Renal failure	37.02	11.95	110	22888	117542	63348482
Treatment failure	36.91	11.95	13	22985	199030	63266994
Alopecia	35.53	11.95	42	22956	337494	63128530
Diabetic retinopathy	34.92	11.95	17	22981	2310	63463714
Lower respiratory tract infection	34.04	11.95	4	22994	132303	63333721
Hypoglycaemic coma	33.29	11.95	17	22981	2558	63463466
Rheumatoid arthritis	33.20	11.95	26	22972	253793	63212231
Discomfort	32.66	11.95	10	22988	167364	63298660
Therapeutic product effect decreased	31.94	11.95	15	22983	193172	63272852
Ureteric cancer	31.71	11.95	7	22991	70	63465954
Product complaint	30.65	11.95	30	22968	12779	63453245
Joint swelling	30.17	11.95	45	22953	327621	63138403
Product use issue	29.59	11.95	22	22976	220498	63245526
Asthenia	29.24	11.95	238	22760	383366	63082658
Blood glucose fluctuation	29.01	11.95	19	22979	4557	63461467
Bladder trabeculation	27.75	11.95	6	22992	54	63465970
Bladder adenocarcinoma stage unspecified	27.45	11.95	5	22993	16	63466008
Pericarditis	27.27	11.95	7	22991	131572	63334452
Fall	26.52	11.95	237	22761	392097	63073927
Myalgia	26.31	11.95	114	22884	146415	63319609
Chest pain	25.99	11.95	150	22848	215809	63250215
Angina unstable	25.69	11.95	21	22977	7074	63458950
General physical health deterioration	24.64	11.95	22	22976	201380	63264644
Biopsy skin abnormal	24.41	11.95	6	22992	99	63465925
Abdominal discomfort	24.15	11.95	50	22948	320835	63145189
Musculoskeletal stiffness	24.02	11.95	19	22979	184599	63281425
Diabetic neuropathy	24.01	11.95	16	22982	3948	63462076
Dehydration	23.93	11.95	125	22873	173229	63292795
Therapeutic product effect incomplete	23.46	11.95	8	22990	125048	63340976
Pancreatitis chronic	22.62	11.95	13	22985	2471	63463553
Nausea	22.56	11.95	434	22564	854037	62611987
Portal fibrosis	22.43	11.95	7	22991	286	63465738
Blood triglycerides increased	22.27	11.95	25	22973	12463	63453561
Cholelithiasis	22.05	11.95	49	22949	43876	63422148
Haematuria	21.23	11.95	38	22960	29119	63436905
Vomiting	20.92	11.95	301	22697	559316	62906708
Fasting	20.71	11.95	4	22994	19	63466005
Radius fracture	20.42	11.95	14	22984	3621	63462403
Ketoacidosis	20.29	11.95	15	22983	4363	63461661
Euglycaemic diabetic ketoacidosis	20.28	11.95	14	22984	3660	63462364
Dyspnoea	20.28	11.95	344	22654	660969	62805055
Exposure during pregnancy	20.24	11.95	16	22982	155531	63310493
Fluid retention	19.90	11.95	57	22941	59629	63406395
Acute myocardial infarction	19.82	11.95	39	22959	32085	63433939
Nasopharyngitis	19.65	11.95	39	22959	254218	63211806
High density lipoprotein decreased	18.81	11.95	11	22987	2159	63463865
Pancreatic carcinoma metastatic	18.78	11.95	11	22987	2167	63463857
Tibia fracture	18.21	11.95	15	22983	5105	63460919
Blood ketone body increased	18.18	11.95	6	22992	294	63465730
Infection	17.84	11.95	35	22963	229138	63236886
Hepatic enzyme increased	17.45	11.95	29	22969	202299	63263725
Ketosis	17.38	11.95	7	22991	606	63465418
Arteriosclerosis coronary artery	17.09	11.95	18	22980	8355	63457669
Intentional product use issue	16.83	11.95	13	22985	127879	63338145
Transitional cell carcinoma	16.81	11.95	7	22991	660	63465364
IIIrd nerve paralysis	16.50	11.95	7	22991	691	63465333
Varicose vein ruptured	16.27	11.95	4	22994	66	63465958
Nicotinic acid deficiency	16.16	11.95	4	22994	68	63465956
Renal impairment	16.04	11.95	69	22929	88286	63377738
Incorrect dose administered	16.02	11.95	53	22945	59915	63406109
Retinal aneurysm	15.98	11.95	5	22993	206	63465818
Stomatitis	15.97	11.95	16	22982	138709	63327315
Rhabdomyolysis	15.66	11.95	43	22955	43908	63422116
Face oedema	15.57	11.95	27	22971	20185	63445839
Visual acuity reduced	15.32	11.95	28	22970	21798	63444226
Ankle fracture	15.28	11.95	25	22973	17830	63448194
Rash	15.24	11.95	130	22868	560741	62905283
Shock	15.10	11.95	29	22969	23434	63442590
Unresponsive to stimuli	15.07	11.95	36	22962	33780	63432244
Left ventricular dysfunction	14.89	11.95	20	22978	11968	63454056
Inflammatory bowel disease	14.89	11.95	12	22986	3961	63462063
Decreased appetite	14.60	11.95	147	22851	250905	63215119
Swelling	14.59	11.95	51	22947	275327	63190697
Hyperkalaemia	14.56	11.95	48	22950	54155	63411869
Blood glucose abnormal	14.42	11.95	16	22982	7876	63458148
Arteriosclerosis	14.39	11.95	18	22980	10048	63455976
Hypersensitivity	14.33	11.95	56	22942	292629	63173395
Acute coronary syndrome	14.31	11.95	18	22980	10108	63455916
Postmortem blood drug level increased	14.09	11.95	6	22992	598	63465426
Adult failure to thrive	13.97	11.95	4	22994	121	63465903
Fibula fracture	13.92	11.95	11	22987	3531	63462493
Cerebrovascular accident	13.61	11.95	76	22922	107948	63358076
Upper airway obstruction	13.21	11.95	6	22992	697	63465327
Cardiomegaly	12.88	11.95	23	22975	17591	63448433
Pain	12.86	11.95	190	22808	740438	62725586
Salpingo-oophorectomy bilateral	12.80	11.95	4	22994	164	63465860
Urine output decreased	12.67	11.95	18	22980	11352	63454672
Retinal haemorrhage	12.57	11.95	12	22986	4957	63461067
Contraindicated product prescribed	12.24	11.95	7	22991	1318	63464706
Gastrointestinal disorder	12.08	11.95	18	22980	131221	63334803
Pleural effusion	12.02	11.95	66	22932	93144	63372880
Generalised oedema	12.01	11.95	21	22977	15797	63450227
Cardiac failure acute	12.00	11.95	16	22982	9507	63456517
Sinusitis	11.99	11.95	42	22956	226611	63239413
Hypertriglyceridaemia	11.97	11.95	13	22985	6246	63459778

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bladder cancer	2327.20	12.22	737	24783	15541	34915870
Bladder transitional cell carcinoma	389.72	12.22	123	25397	2532	34928879
Blood glucose increased	261.23	12.22	281	25239	66437	34864974
Hypoglycaemia	251.44	12.22	251	25269	54389	34877022
Cardiac failure congestive	148.24	12.22	238	25282	83032	34848379
Diabetes mellitus inadequate control	141.97	12.22	100	25420	13364	34918047
Pancreatitis	136.79	12.22	155	25365	38736	34892675
Glycosylated haemoglobin increased	128.26	12.22	88	25432	11272	34920139
Oedema peripheral	102.66	12.22	252	25268	119560	34811851
Haematuria	100.02	12.22	151	25369	49915	34881496
Pancreatic carcinoma	88.96	12.22	64	25456	8837	34922574
Diabetic ketoacidosis	84.94	12.22	84	25436	17948	34913463
Bladder neoplasm	82.98	12.22	33	25487	1355	34930056
Off label use	69.90	12.22	125	25395	419399	34512012
Blood glucose decreased	66.72	12.22	64	25456	13173	34918238
Myocardial infarction	63.03	12.22	213	25307	120872	34810539
Transitional cell carcinoma	62.54	12.22	31	25489	2158	34929253
Macular oedema	54.20	12.22	31	25489	2883	34928528
Ureteric cancer	48.90	12.22	14	25506	203	34931208
Drug ineffective	48.10	12.22	172	25348	456579	34474832
Weight increased	46.92	12.22	162	25358	92871	34838540
Toxicity to various agents	46.11	12.22	47	25473	200315	34731096
Oedema	45.38	12.22	102	25418	45639	34885772
Malignant spinal cord compression	43.93	12.22	12	25508	145	34931266
Diabetic nephropathy	43.26	12.22	24	25496	2104	34929307
Hyperglycaemia	41.38	12.22	90	25430	39390	34892021
Pancreatitis acute	40.15	12.22	73	25447	28068	34903343
Product use in unapproved indication	39.76	12.22	18	25502	117481	34813930
Coronary artery disease	38.54	12.22	99	25421	48206	34883205
Bladder cancer recurrent	36.55	12.22	13	25507	390	34931021
Genital infection fungal	36.21	12.22	11	25509	198	34931213
Bladder cancer stage 0, with cancer in situ	35.48	12.22	8	25512	40	34931371
Diabetic metabolic decompensation	30.75	12.22	18	25502	1748	34929663
Pemphigoid	29.52	12.22	34	25486	8632	34922779
Meningitis eosinophilic	29.29	12.22	6	25514	17	34931394
Product complaint	28.77	12.22	28	25492	5862	34925549
Acute myocardial infarction	28.33	12.22	95	25425	53624	34877787
Diabetic retinopathy	27.69	12.22	17	25503	1800	34929611
Gallbladder neoplasm	26.45	12.22	6	25514	31	34931380
Death	26.10	12.22	177	25343	397872	34533539
Hypoglycaemic coma	25.48	12.22	18	25502	2413	34928998
General physical health deterioration	25.27	12.22	34	25486	128235	34803176
Euglycaemic diabetic ketoacidosis	25.17	12.22	20	25500	3202	34928209
Intentional product use issue	23.88	12.22	7	25513	59809	34871602
Treatment failure	23.82	12.22	3	25517	46694	34884717
Cerebral infarction	23.70	12.22	58	25462	27397	34904014
Bladder papilloma	21.70	12.22	5	25515	28	34931383
Cardiac failure	20.99	12.22	126	25394	91122	34840289
Infectious mononucleosis	20.87	12.22	10	25510	646	34930765
Urethral cancer	20.47	12.22	6	25514	95	34931316
Renal cyst	20.41	12.22	29	25491	9064	34922347
Pleural effusion	20.31	12.22	115	25405	81431	34849980
Anti-insulin antibody positive	20.31	12.22	7	25513	191	34931220
Overdose	20.19	12.22	22	25498	91037	34840374
Malignant neoplasm of renal pelvis	19.94	12.22	5	25515	42	34931369
Pollakiuria	19.64	12.22	44	25476	19630	34911781
Bladder transitional cell carcinoma stage III	19.44	12.22	5	25515	47	34931364
Cerebrovascular accident	18.80	12.22	116	25404	84695	34846716
Weight decreased	18.78	12.22	204	25316	176097	34755314
Diabetic neuropathy	18.74	12.22	19	25501	4178	34927233
Urine cytology abnormal	18.67	12.22	3	25517	0	34931411
Type 2 diabetes mellitus	18.47	12.22	38	25482	15994	34915417
Thrombocytopenia	18.29	12.22	56	25464	156191	34775220
Bladder transitional cell carcinoma stage II	18.26	12.22	5	25515	61	34931350
Foetal exposure during pregnancy	18.15	12.22	3	25517	38098	34893313
Product use issue	18.01	12.22	12	25508	63204	34868207
Hepatic cancer	18.00	12.22	26	25494	8249	34923162
Pulmonary oedema	17.54	12.22	75	25445	47454	34883957
Pyrexia	16.74	12.22	159	25361	332854	34598557
Blood creatine phosphokinase increased	16.72	12.22	71	25449	44786	34886625
Abnormal weight gain	16.60	12.22	10	25510	1024	34930387
Prostate cancer	16.55	12.22	65	25455	39584	34891827
Blood glucose abnormal	16.44	12.22	21	25499	5931	34925480
Drug intolerance	16.06	12.22	12	25508	59558	34871853
Metastatic carcinoma of the bladder	15.97	12.22	6	25514	211	34931200
Post-thoracotomy pain syndrome	15.71	12.22	4	25516	36	34931375
Interstitial lung disease	15.55	12.22	91	25429	65191	34866220
Bladder adenocarcinoma stage unspecified	15.38	12.22	3	25517	6	34931405
Febrile neutropenia	15.34	12.22	50	25470	136799	34794612
Angina pectoris	15.25	12.22	54	25466	31309	34900102
Isosporiasis	15.23	12.22	5	25515	117	34931294
Retinal aneurysm	14.99	12.22	5	25515	123	34931288
Insulin resistance	14.98	12.22	8	25512	650	34930761
Loss of consciousness	14.67	12.22	107	25413	82560	34848851
Angina unstable	13.87	12.22	28	25492	11625	34919786
Rectal cancer	13.71	12.22	12	25508	2195	34929216
Diabetes mellitus	13.63	12.22	69	25451	46804	34884607
Pancreatitis chronic	13.55	12.22	12	25508	2228	34929183
Hypoglycaemic unconsciousness	13.54	12.22	8	25512	790	34930621
Sleep talking	13.51	12.22	7	25513	535	34930876
Hepatic function abnormal	13.40	12.22	66	25454	44297	34887114
Neutropenia	13.30	12.22	64	25456	156714	34774697
Urogenital infection fungal	13.14	12.22	3	25517	16	34931395
Aortic stenosis	13.03	12.22	16	25504	4342	34927069
Metastases to liver	13.02	12.22	30	25490	13633	34917778
Diabetic retinal oedema	12.94	12.22	5	25515	190	34931221
Blood urine present	12.86	12.22	26	25494	10808	34920603
Blood urea increased	12.85	12.22	50	25470	30314	34901097
Rheumatoid arthritis	12.70	12.22	6	25514	38232	34893179
Cholelithiasis	12.59	12.22	39	25481	21109	34910302

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bladder cancer	2279.04	11.42	688	37816	18838	79687046
Hypoglycaemia	616.39	11.42	458	38046	101136	79604748
Blood glucose increased	481.07	11.42	417	38087	114558	79591326
Bladder transitional cell carcinoma	467.61	11.42	129	38375	2521	79703363
Cardiac failure congestive	260.41	11.42	332	38172	142070	79563814
Diabetes mellitus inadequate control	257.27	11.42	155	38349	24109	79681775
Diabetic ketoacidosis	213.67	11.42	157	38347	33965	79671919
Oedema peripheral	181.91	11.42	386	38118	251902	79453982
Glycosylated haemoglobin increased	173.67	11.42	111	38393	19149	79686735
Haematuria	144.23	11.42	172	38332	68664	79637220
Bladder neoplasm	135.08	11.42	45	38459	1692	79704192
Blood glucose decreased	134.10	11.42	107	38397	26127	79679757
Myocardial infarction	117.04	11.42	268	38236	183861	79522023
Pancreatitis	111.42	11.42	151	38353	68424	79637460
Pancreatic carcinoma	107.15	11.42	72	38432	13505	79692379
Diabetic metabolic decompensation	106.54	11.42	45	38459	3287	79702597
Drug ineffective	97.30	11.42	239	38265	1080674	78625210
Off label use	96.17	11.42	183	38321	907032	78798852
Cardiac failure	88.19	11.42	216	38288	154626	79551258
Hyperglycaemia	86.79	11.42	136	38368	70199	79635685
Macular oedema	85.23	11.42	45	38459	5429	79700455
Ureteric cancer	83.87	11.42	21	38483	276	79705608
Oedema	80.33	11.42	178	38326	119402	79586482
Transitional cell carcinoma	76.88	11.42	33	38471	2508	79703376
Weight increased	72.21	11.42	295	38209	277091	79428793
Coronary artery disease	69.13	11.42	118	38386	65356	79640528
Drug intolerance	67.01	11.42	22	38482	264097	79441787
Diabetic retinopathy	61.39	11.42	30	38474	3076	79702808
Acute myocardial infarction	57.84	11.42	120	38384	76916	79628968
Drug abuse	54.70	11.42	7	38497	162684	79543200
Hypoglycaemic coma	54.58	11.42	32	38472	4728	79701156
Pancreatitis acute	54.48	11.42	91	38413	49513	79656371
Infusion related reaction	52.03	11.42	23	38481	230214	79475670
Euglycaemic diabetic ketoacidosis	50.92	11.42	35	38469	6809	79699075
Lactic acidosis	49.80	11.42	107	38397	70252	79635632
Malignant spinal cord compression	48.70	11.42	12	38492	147	79705737
Rheumatoid arthritis	48.42	11.42	20	38484	208450	79497434
Diabetic nephropathy	48.08	11.42	25	38479	2922	79702962
Bladder cancer stage 0, with cancer in situ	47.22	11.42	10	38494	58	79705826
Treatment failure	45.39	11.42	13	38491	170473	79535411
Pemphigoid	43.68	11.42	45	38459	15270	79690614
Bladder cancer recurrent	42.47	11.42	14	38490	509	79705375
Bladder adenocarcinoma stage unspecified	40.64	11.42	8	38496	30	79705854
Genital infection fungal	40.50	11.42	11	38493	202	79705682
General physical health deterioration	40.36	11.42	44	38460	275194	79430690
Diabetes mellitus	39.03	11.42	104	38400	78286	79627598
Diabetic neuropathy	37.54	11.42	28	38476	6188	79699696
Maternal exposure during pregnancy	37.11	11.42	10	38494	136528	79569356
Contraindicated product administered	36.76	11.42	15	38489	157523	79548361
Cerebral infarction	36.47	11.42	73	38431	45603	79660281
Rhabdomyolysis	36.29	11.42	121	38383	103010	79602874
Lower respiratory tract infection	36.00	11.42	9	38495	129211	79576673
Angina unstable	35.75	11.42	42	38462	16485	79689399
Product use in unapproved indication	35.64	11.42	41	38463	250318	79455566
Product use issue	33.67	11.42	31	38473	209791	79496093
Glossodynia	33.42	11.42	5	38499	103332	79602552
Intentional product use issue	33.11	11.42	16	38488	152096	79553788
Cerebrovascular accident	32.62	11.42	155	38349	155137	79550747
Pulmonary oedema	32.35	11.42	105	38399	88149	79617735
Bladder papilloma	32.03	11.42	6	38498	16	79705868
Pleural effusion	31.99	11.42	147	38357	145115	79560769
Pericarditis	31.59	11.42	6	38498	104230	79601654
Urine cytology abnormal	30.83	11.42	5	38499	3	79705881
Dehydration	30.63	11.42	215	38289	247972	79457912
Retinal aneurysm	28.98	11.42	9	38495	269	79705615
Renal failure	28.97	11.42	181	38323	200787	79505097
Chest pain	28.89	11.42	234	38270	282070	79423814
Toxicity to various agents	28.51	11.42	106	38398	421434	79284450
Blood creatine phosphokinase increased	28.28	11.42	83	38421	66007	79639877
Alopecia	27.72	11.42	43	38461	231312	79474572
Retinal haemorrhage	26.85	11.42	26	38478	8191	79697693
Weight decreased	26.49	11.42	275	38229	354923	79350961
Meningitis eosinophilic	26.26	11.42	5	38499	15	79705869
Ketoacidosis	25.95	11.42	25	38479	7829	79698055
Product complaint	25.73	11.42	32	38472	13317	79692567
Bladder trabeculation	25.64	11.42	6	38498	58	79705826
Urethral cancer	24.78	11.42	6	38498	68	79705816
Exposure during pregnancy	24.63	11.42	9	38495	101123	79604761
Hypersensitivity	24.19	11.42	57	38447	262182	79443702
Arthropathy	24.13	11.42	30	38474	177081	79528803
Wound	24.11	11.42	13	38491	116166	79589718
Pancreatitis chronic	24.04	11.42	18	38486	4001	79701883
Prostate cancer	24.00	11.42	51	38453	33217	79672667
Blood triglycerides increased	23.63	11.42	39	38465	21001	79684883
Gallbladder neoplasm	23.55	11.42	6	38498	85	79705799
Blood glucose fluctuation	23.46	11.42	22	38482	6660	79699224
Visual acuity reduced	23.40	11.42	47	38457	29422	79676462
Fluid retention	22.88	11.42	80	38424	69729	79636155
Joint swelling	22.64	11.42	68	38436	288578	79417306
Therapeutic product effect incomplete	22.63	11.42	21	38483	141624	79564260
Acute kidney injury	22.56	11.42	364	38140	519040	79186844
Musculoskeletal stiffness	22.45	11.42	31	38473	174977	79530907
Hepatic function abnormal	22.44	11.42	82	38422	73025	79632859
Peripheral swelling	22.25	11.42	62	38442	269555	79436329
Pain	22.22	11.42	225	38279	703577	79002307
Discomfort	22.06	11.42	17	38487	125600	79580284
Hepatic cancer	21.52	11.42	26	38478	10503	79695381
Febrile neutropenia	21.47	11.42	50	38454	230949	79474935
Bladder transitional cell carcinoma stage III	21.13	11.42	5	38499	51	79705833
Coronary artery occlusion	20.83	11.42	31	38473	15284	79690600
Psoriatic arthropathy	20.65	11.42	6	38498	77993	79627891
Blood ketone body increased	20.61	11.42	9	38495	713	79705171
Cholelithiasis	20.52	11.42	64	38440	52600	79653284
Insulin resistance	20.52	11.42	11	38493	1368	79704516
Anti-insulin antibody positive	20.38	11.42	7	38497	289	79705595
Angina pectoris	20.28	11.42	63	38441	51669	79654215
Blood glucose abnormal	19.84	11.42	25	38479	10541	79695343
Fall	19.79	11.42	338	38166	487291	79218593
Nasopharyngitis	19.77	11.42	60	38444	253821	79452063
Lacunar infarction	19.75	11.42	19	38485	5938	79699946
Cardiomegaly	19.71	11.42	41	38463	26311	79679573
High density lipoprotein decreased	19.65	11.42	17	38487	4638	79701246
Ill-defined disorder	19.52	11.42	4	38500	65871	79640013
Pyrexia	19.40	11.42	222	38282	678487	79027397
IIIrd nerve paralysis	19.12	11.42	10	38494	1183	79704701
Bladder transitional cell carcinoma stage II	19.11	11.42	5	38499	79	79705805
Diabetic retinal oedema	19.06	11.42	7	38497	352	79705532
Biopsy skin abnormal	18.90	11.42	6	38498	193	79705691
Renal cyst	18.87	11.42	29	38475	14703	79691181
Stomatitis	18.82	11.42	26	38478	146731	79559153
Retinal exudates	18.79	11.42	10	38494	1225	79704659
Pancreatic carcinoma metastatic	18.52	11.42	15	38489	3738	79702146
Renal cell carcinoma	18.17	11.42	19	38485	6559	79699325
Hydronephrosis	17.81	11.42	31	38473	17423	79688461
Rash	17.78	11.42	186	38318	578172	79127712
Duodenal ulcer perforation	17.70	11.42	5	38499	66206	79639678
Arthralgia	17.54	11.42	184	38320	571619	79134265
Helicobacter infection	17.32	11.42	6	38498	69698	79636186
Folliculitis	17.19	11.42	3	38501	55377	79650507
Low density lipoprotein increased	17.15	11.42	21	38483	8601	79697283
Blood urea increased	16.94	11.42	57	38447	48733	79657151
Ketosis	16.80	11.42	9	38495	1117	79704767
Malignant neoplasm of renal pelvis	16.80	11.42	5	38499	129	79705755
Face oedema	16.79	11.42	40	38464	28096	79677788
Decreased appetite	16.77	11.42	245	38259	342173	79363711
Aortic stenosis	16.13	11.42	19	38485	7476	79698408
Fasting	15.81	11.42	4	38500	55	79705829
Fatigue	15.74	11.42	336	38168	929391	78776493
Diabetic complication	15.73	11.42	9	38495	1270	79704614
Microalbuminuria	15.59	11.42	8	38496	910	79704974
Blood creatinine increased	15.55	11.42	128	38376	154929	79550955
Chronic gastritis	15.46	11.42	14	38490	4054	79701830
Portal fibrosis	15.35	11.42	7	38497	614	79705270
Transient ischaemic attack	15.25	11.42	58	38446	52637	79653247
Multiple injuries	15.23	11.42	13	38491	3482	79702402
Isosporiasis	15.14	11.42	5	38499	183	79705701
Peripheral vascular disorder	15.08	11.42	19	38485	8011	79697873
Radius fracture	15.01	11.42	13	38491	3551	79702333
Hypoglycaemic encephalopathy	14.94	11.42	7	38497	654	79705230
Mucosal inflammation	14.90	11.42	9	38495	75571	79630313
Cardiac failure acute	14.80	11.42	30	38474	18899	79686985
Therapeutic product effect decreased	14.80	11.42	36	38468	163827	79542057
Blood pressure fluctuation	14.70	11.42	7	38497	67138	79638746
Fibula fracture	14.67	11.42	13	38491	3661	79702223
Cardiovascular disorder	14.61	11.42	29	38475	17996	79687888
Death	14.39	11.42	190	38314	566324	79139560
Infection	14.29	11.42	64	38440	241648	79464236
Adenocarcinoma pancreas	14.19	11.42	10	38494	2023	79703861
Asthenia	14.17	11.42	335	38169	511354	79194530
Infectious mononucleosis	14.15	11.42	10	38494	2032	79703852
Cardiac disorder	14.06	11.42	66	38438	65691	79640193
Abnormal weight gain	13.97	11.42	11	38493	2633	79703251
Sinusitis	13.96	11.42	48	38456	195453	79510431
Urogenital infection fungal	13.94	11.42	3	38501	19	79705865
Treatment noncompliance	13.88	11.42	56	38448	52212	79653672
Condition aggravated	13.87	11.42	165	38339	500959	79204925
Metastatic carcinoma of the bladder	13.78	11.42	5	38499	243	79705641
Hypoglycaemic unconsciousness	13.69	11.42	8	38496	1175	79704709
Pollakiuria	13.31	11.42	44	38460	37273	79668611
Therapy non-responder	13.25	11.42	15	38489	92290	79613594
Arteriosclerosis	13.21	11.42	28	38476	18199	79687685
Rectal cancer	13.18	11.42	12	38492	3501	79702383
Nausea	13.16	11.42	576	37928	956620	78749264
Renal impairment	13.11	11.42	125	38379	157658	79548226
Urine ketone body present	13.02	11.42	12	38492	3553	79702331
Polydipsia	13.00	11.42	16	38488	6589	79699295
Salpingo-oophorectomy bilateral	12.92	11.42	3	38501	28	79705856
Coma	12.73	11.42	18	38486	100631	79605253
Dilatation atrial	12.63	11.42	12	38492	3692	79702192
Interstitial lung disease	12.41	11.42	95	38409	112505	79593379
Ventricular hypertrophy	12.37	11.42	16	38488	6922	79698962
Varicose vein ruptured	12.36	11.42	4	38500	137	79705747
Nocturia	12.30	11.42	23	38481	13658	79692226
Hepatic enzyme increased	12.27	11.42	46	38458	182564	79523320
Tibia fracture	12.22	11.42	14	38490	5347	79700537
Loss of control of legs	12.20	11.42	9	38495	1956	79703928
Cellulitis	12.01	11.42	92	38412	108968	79596916
Neuropathic arthropathy	11.90	11.42	5	38499	360	79705524
Dry mouth	11.89	11.42	15	38489	88004	79617880
Adverse drug reaction	11.63	11.42	9	38495	66383	79639501
Sleep talking	11.61	11.42	7	38497	1089	79704795
Renal cancer	11.56	11.42	21	38483	12205	79693679
Humerus fracture	11.47	11.42	18	38486	9295	79696589
Urine flow decreased	11.46	11.42	7	38497	1114	79704770

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10BD05	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BD06	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BD09	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BD12	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BG03	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Thiazolidinediones
FDA CS	M0199111	PPAR alpha
FDA CS	M0199114	PPAR gamma
FDA CS	M0447306	Thiazolidinediones
FDA MoA	N0000175374	Peroxisome Proliferator-activated Receptor Activity
FDA MoA	N0000175375	Peroxisome Proliferator-activated Receptor alpha Agonists
FDA MoA	N0000175377	Peroxisome Proliferator-activated Receptor gamma Agonists
MeSH PA	D007004	Hypoglycemic Agents
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:35526	antidiabetic
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:50864	insulin sensitizers
CHEBI has role	CHEBI:71554	PPARgamma agonist
CHEBI has role	CHEBI:77194	ATP:pantothenate 4-phosphotransferase inhibitor
CHEBI has role	CHEBI:77307	cardioprotective agents
CHEBI has role	CHEBI:83157	EC 6.2.1.3 inhibitors
CHEBI has role	CHEBI:173084	ferroptosis inhibitors
CHEBI has role	CHEBI:176497	geroprotectors
FDA EPC	N0000175596	Peroxisome Proliferator Receptor alpha Agonist
FDA EPC	N0000180186	Peroxisome Proliferator Receptor gamma Agonist
FDA EPC	N0000180190	Thiazolidinedione

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352
Alcoholism	contraindication	7200002
Asthenia	contraindication	13791008
Myocardial infarction	contraindication	22298006	DOID:5844
Acute vomiting	contraindication	23971007
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Dehydration	contraindication	34095006
Macular retinal edema	contraindication	37231002	DOID:4449
Infectious disease	contraindication	40733004
Body fluid retention	contraindication	43498006
Chronic heart failure	contraindication	48447003
Hepatic porphyria	contraindication	55056006	DOID:3133
Ketoacidosis	contraindication	56051008
Metabolic acidosis	contraindication	59455009
Hemolytic anemia	contraindication	61261009	DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia	contraindication	62403005
Hypopituitarism	contraindication	74728003	DOID:9406
Cardiogenic shock	contraindication	89138009
Kidney disease	contraindication	90708001	DOID:557
Lactic acidosis	contraindication	91273001	DOID:3650
Fracture of bone	contraindication	125605004
Autonomic dysreflexia	contraindication	129618003
Liver function tests abnormal	contraindication	166603001
Cobalamin deficiency	contraindication	190634004
Decompensated cardiac failure	contraindication	195111005
Disease of liver	contraindication	235856003	DOID:409
Hypoglycemic disorder	contraindication	237630007
Sepsis syndrome	contraindication	238150007
Edema	contraindication	267038008
Primary adrenocortical insufficiency	contraindication	373662000
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Fever	contraindication	386661006
Surgical procedure	contraindication	387713003
Malignant tumor of urinary bladder	contraindication	399326009	DOID:11054
Severe diarrhea	contraindication	409587002
Breastfeeding (mother)	contraindication	413712001
Traumatic injury	contraindication	417746004
Fever greater than 100.4 Fahrenheit	contraindication	426000000
Radiography with IV Iodinated Contrast Agent	contraindication
Severe Hypoxemia	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.33	acidic
pKa2	7.15	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 12.5MG BASE;EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	DISCN	TABLET	ORAL	8173663	March 15, 2025	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE;EQ 30MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	8173663	March 15, 2025	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE;EQ 45MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	DISCN	TABLET	ORAL	8173663	March 15, 2025	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 25MG BASE;EQ 15MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	8173663	March 15, 2025	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 25MG BASE;EQ 30MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	8173663	March 15, 2025	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 25MG BASE;EQ 45MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	8173663	March 15, 2025	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE;EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	DISCN	TABLET	ORAL	7807689	June 27, 2028	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;EQ 30MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	7807689	June 27, 2028	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;EQ 45MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	DISCN	TABLET	ORAL	7807689	June 27, 2028	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE;EQ 15MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	7807689	June 27, 2028	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE;EQ 30MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	7807689	June 27, 2028	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE;EQ 45MG BASE	OSENI	TAKEDA PHARMS USA	N022426	Jan. 25, 2013	RX	TABLET	ORAL	7807689	June 27, 2028	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Peroxisome proliferator-activated receptor gamma	Nuclear hormone receptor	P37231	PPARG_HUMAN	AGONIST	EC50	6.23	WOMBAT-PK	CHEMBL
Bile salt export pump	Transporter	O95342	ABCBB_HUMAN		IC50	6.52	CHEMBL
Amine oxidase [flavin-containing] B	Enzyme	P27338	AOFB_HUMAN		Ki	6.30	CHEMBL
Amine oxidase [flavin-containing] A	Enzyme	P21397	AOFA_HUMAN		IC50	4.46	DRUG MATRIX
Peroxisome proliferator-activated receptor alpha	Nuclear hormone receptor	Q07869	PPARA_HUMAN		EC50	5.18	CHEMBL
CDGSH iron-sulfur domain-containing protein 1	Unclassified	Q9NZ45	CISD1_HUMAN		Ki	6.43	CHEMBL
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		IC50	6.94	DRUG MATRIX
CDGSH iron-sulfur domain-containing protein 2	Unclassified	Q8N5K1	CISD2_HUMAN		IC50	5.32	CHEMBL
Aldose reductase	Enzyme		ALDR_RAT		IC50	4.88	DRUG MATRIX
Amine oxidase [flavin-containing] B	Enzyme		AOFB_RAT		Ki	5.68	CHEMBL
Peroxisome proliferator-activated receptor alpha	Transcription factor		PPARA_MOUSE		IC50	5.94	CHEMBL
Peroxisome proliferator-activated receptor gamma	Transcription factor		PPARG_MOUSE		IC50	6.15	CHEMBL
Peroxisome proliferator-activated receptor gamma	Transcription factor		PPARG_RAT		IC50	6.15	CHEMBL
Enoyl-[acyl-carrier-protein] reductase [NADH]	Enzyme		Q5NGQ3_FRATT		IC50	4.10	CHEMBL
Bile salt export pump	Transporter		ABCBB_RAT		IC50	5.70	CHEMBL
CDGSH iron-sulfur domain-containing protein 1	Unclassified		CISD1_RAT		IC50	6	CHEMBL

External reference:

ID	Source
4021165	VUID
N0000148616	NUI
D00945	KEGG_DRUG
112529-15-4	SECONDARY_CAS_RN
4021165	VANDF
4021166	VANDF
4029214	VANDF
C0071097	UMLSCUI
CHEBI:8228	CHEBI
8N6	PDB_CHEM_ID
CHEMBL595	ChEMBL_ID
DB01132	DRUGBANK_ID
CHEMBL1715	ChEMBL_ID
D000077205	MESH_DESCRIPTOR_UI
4829	PUBCHEM_CID
2694	IUPHAR_LIGAND_ID
6343	INN_ID
X4OV71U42S	UNII
259319	RXNORM
178611	MMSL
29092	MMSL
35713	MMSL
8258	MMSL
d04442	MMSL
007823	NDDF
007824	NDDF
116097005	SNOMEDCT_US
326058001	SNOMEDCT_US
395828009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7271	TABLET	15 mg	ORAL	ANDA	29 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7271	TABLET	15 mg	ORAL	ANDA	29 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7272	TABLET	30 mg	ORAL	ANDA	29 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7272	TABLET	30 mg	ORAL	ANDA	29 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7273	TABLET	45 mg	ORAL	ANDA	29 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7273	TABLET	45 mg	ORAL	ANDA	29 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5420	TABLET	15 mg	ORAL	ANDA	28 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5421	TABLET	30 mg	ORAL	ANDA	28 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5422	TABLET	45 mg	ORAL	ANDA	28 sections
Pioglitazone and metformin	HUMAN PRESCRIPTION DRUG LABEL	2	0781-5626	TABLET, FILM COATED	15 mg	ORAL	ANDA	29 sections
Pioglitazone and metformin	HUMAN PRESCRIPTION DRUG LABEL	2	0781-5627	TABLET, FILM COATED	15 mg	ORAL	ANDA	29 sections
Pioglitazone hydrochloride and glimepiride	HUMAN PRESCRIPTION DRUG LABEL	2	0781-5634	TABLET	30 mg	ORAL	ANDA	28 sections
Pioglitazone hydrochloride and glimepiride	HUMAN PRESCRIPTION DRUG LABEL	2	0781-5635	TABLET	30 mg	ORAL	ANDA	28 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7090	TABLET	15 mg	ORAL	ANDA	30 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7090	TABLET	15 mg	ORAL	ANDA	30 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7096	TABLET	30 mg	ORAL	ANDA	30 sections
Pioglitazone	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7096	TABLET	30 mg	ORAL	ANDA	30 sections
PIOGLITAZONEHYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-119	TABLET	30 mg	ORAL	ANDA	26 sections
PIOGLITAZONEHYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-120	TABLET	45 mg	ORAL	ANDA	26 sections
PIOGLITAZONEHYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-140	TABLET	15 mg	ORAL	ANDA	26 sections
Pioglitazone HCL and Metformin HCL	HUMAN PRESCRIPTION DRUG LABEL	2	13668-280	TABLET	15 mg	ORAL	ANDA	28 sections
Pioglitazone HCL and Metformin HCL	HUMAN PRESCRIPTION DRUG LABEL	2	13668-281	TABLET	15 mg	ORAL	ANDA	28 sections
Pioglitazone	Human Prescription Drug Label	1	16714-645	TABLET	15 mg	ORAL	ANDA	30 sections
Pioglitazone	Human Prescription Drug Label	1	16714-646	TABLET	30 mg	ORAL	ANDA	30 sections
Pioglitazone	Human Prescription Drug Label	1	16714-647	TABLET	45 mg	ORAL	ANDA	30 sections
PIOGLITAZONE	HUMAN PRESCRIPTION DRUG LABEL	1	16729-020	TABLET	15 mg	ORAL	ANDA	29 sections
PIOGLITAZONE	HUMAN PRESCRIPTION DRUG LABEL	1	16729-020	TABLET	15 mg	ORAL	ANDA	29 sections
PIOGLITAZONE	HUMAN PRESCRIPTION DRUG LABEL	1	16729-021	TABLET	30 mg	ORAL	ANDA	29 sections
PIOGLITAZONE	HUMAN PRESCRIPTION DRUG LABEL	1	16729-021	TABLET	30 mg	ORAL	ANDA	29 sections
PIOGLITAZONE	HUMAN PRESCRIPTION DRUG LABEL	1	16729-022	TABLET	45 mg	ORAL	ANDA	29 sections